BriaCell Therapeutics Corp. (BCTX) Insider Trading Activity

NASDAQ$3.205+0.2 (6.64%)
Market Cap
$26.28M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
440 of 849
Rank in Industry
258 of 491

BCTX Insider Trading Activity

BCTX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This …

Insider Activity of BriaCell Therapeutics Corp.

Over the last 12 months, insiders at BriaCell Therapeutics Corp. have bought $0 and sold $0 worth of BriaCell Therapeutics Corp. stock.

On average, over the past 5 years, insiders at BriaCell Therapeutics Corp. have bought $1.12M and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 902,935 shares for transaction amount of $2M was made by Lustig Marc () on 2024‑05‑14.

List of Insider Buy and Sell Transactions, BriaCell Therapeutics Corp.

2024-05-14PurchaseLustig Marc
902,935
5.6265%
$2.21
$2M
-69.83%
2022-12-28PurchaseBondarenko JamiesonChairman
28,000
0.3608%
$4.58
$128,240
+40.81%
2022-12-20PurchaseBondarenko Jamiesondirector
22,000
0.3311%
$5.35
$117,700
+21.44%
Total: 3

BCTX Institutional Investors: Active Positions

Increased Positions7+58.33%8,400+67.18%
Decreased Positions3-25%11,207-89.63%
New Positions3New4,046New
Sold Out Positions3Sold Out11,207Sold Out
Total Postitions16+33.33%9,696-22.45%

BCTX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Citadel Advisors Llc$79.000.55%11,055+11,055New2025-09-30
Federation Des Caisses Desjardins Du Quebec$6.000.05%905+555+158.57%2025-09-30
Morgan Stanley$1.000.01%114+113+11,300%2025-09-30
Royal Bank Of Canada$1.000.01%100-7-6.54%2025-09-30
Sbi Securities Co., Ltd.$1.00<0.01%80+20+33.33%2025-09-30
Osaic Holdings, Inc.$1.00<0.01%72+65+928.57%2025-09-30
Group One Trading Llc$1.00<0.01%70<1-1.41%2025-09-30
Ubs Group Ag$0<0.01%64-1,460-95.8%2025-09-30
Td Waterhouse Canada Inc.$0<0.01%1900%2025-09-30
Fny Investment Advisers, Llc$0<0.01%1000%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.